HRP20192353T1 - Metoda određivanja mutacijskog statusa pik3ca u uzorku - Google Patents

Metoda određivanja mutacijskog statusa pik3ca u uzorku Download PDF

Info

Publication number
HRP20192353T1
HRP20192353T1 HRP20192353TT HRP20192353T HRP20192353T1 HR P20192353 T1 HRP20192353 T1 HR P20192353T1 HR P20192353T T HRP20192353T T HR P20192353TT HR P20192353 T HRP20192353 T HR P20192353T HR P20192353 T1 HRP20192353 T1 HR P20192353T1
Authority
HR
Croatia
Prior art keywords
sequence
seq
dna
allele
cancer
Prior art date
Application number
HRP20192353TT
Other languages
English (en)
Croatian (hr)
Inventor
Evrykleia LIANIDOU
Athina Markou
Original Assignee
Pharmassist Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmassist Ltd filed Critical Pharmassist Ltd
Publication of HRP20192353T1 publication Critical patent/HRP20192353T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/186—Modifications characterised by incorporating a non-extendable or blocking moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00—Reactions demanding special reaction conditions
    • C12Q2527/107—Temperature of melting, i.e. Tm
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
HRP20192353TT 2014-08-07 2015-07-28 Metoda određivanja mutacijskog statusa pik3ca u uzorku HRP20192353T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034231P 2014-08-07 2014-08-07
EP15753745.7A EP3198026B1 (en) 2014-08-07 2015-07-28 Method of determining pik3ca mutational status in a sample
PCT/GR2015/000036 WO2016020710A1 (en) 2014-08-07 2015-07-28 Method of determining pik3ca mutational status in a sample

Publications (1)

Publication Number Publication Date
HRP20192353T1 true HRP20192353T1 (hr) 2020-03-20

Family

ID=53938365

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192353TT HRP20192353T1 (hr) 2014-08-07 2015-07-28 Metoda određivanja mutacijskog statusa pik3ca u uzorku

Country Status (18)

Country Link
US (1) US11279979B2 (enExample)
EP (1) EP3198026B1 (enExample)
JP (1) JP6770957B2 (enExample)
CN (1) CN106715723B (enExample)
CA (1) CA2957396C (enExample)
CY (1) CY1122647T1 (enExample)
DK (1) DK3198026T3 (enExample)
ES (1) ES2764423T3 (enExample)
HR (1) HRP20192353T1 (enExample)
HU (1) HUE047958T2 (enExample)
IL (1) IL250392B (enExample)
LT (1) LT3198026T (enExample)
PL (1) PL3198026T3 (enExample)
PT (1) PT3198026T (enExample)
RS (1) RS59710B1 (enExample)
SI (1) SI3198026T1 (enExample)
SM (1) SMT202000005T1 (enExample)
WO (1) WO2016020710A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102315754B1 (ko) 2010-05-14 2021-10-22 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
WO2015039024A1 (en) 2013-09-16 2015-03-19 Oregon Health & Science University Bioabsorbable clips and applicator for tissue closure
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CA2965986C (en) 2014-11-03 2019-05-07 Oregon Health & Science University Clips and applicator for tissue closure
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
EP3358020B1 (en) * 2017-01-05 2021-05-19 Biodesix, Inc. Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole blood
WO2018140391A1 (en) * 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP7457642B2 (ja) 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
CN107287309A (zh) * 2017-07-06 2017-10-24 罗保君 一种血液循环肿瘤dna点突变检测方法
KR102662580B1 (ko) * 2017-07-26 2024-05-03 세키스이 메디칼 가부시키가이샤 변이 유전자 검출 방법
CN109295175A (zh) * 2017-09-08 2019-02-01 广州健天基因技术有限公司 用于检测人胃肠道间质瘤c-kit基因v559a突变的引物、检测方法及试剂盒
CN109306374A (zh) * 2017-09-08 2019-02-05 广州健天基因技术有限公司 用于检测人类pik3ca基因e545k突变的引物、检测方法及试剂盒
JP7306618B2 (ja) * 2017-09-26 2023-07-11 東ソー株式会社 がんの転移形成能に関与する因子および前記因子を用いたがん患者の予後予測方法
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN107937490A (zh) * 2018-01-15 2018-04-20 福建农林大学 一种非对称pcr的试纸条检测植物病原菌的方法及试剂盒
EP3752643B1 (en) * 2018-02-12 2024-01-17 F. Hoffmann-La Roche AG Method of predicting response to therapy by assessing tumor genetic heterogeneity
CA3103983A1 (en) 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
CN109666747A (zh) * 2019-02-20 2019-04-23 天津脉络医学检验有限公司 一种引物探针组合物及其应用
US11812966B2 (en) 2020-04-24 2023-11-14 NeuraMedica Inc. Clips, appliers, and cartridges
CN113930500B (zh) * 2020-07-13 2024-11-19 铭炽生物科技(上海)有限公司 人pik3ca基因突变的数字pcr检测方法及应用
CN112951325B (zh) * 2021-02-18 2023-04-21 北京吉因加医学检验实验室有限公司 一种用于癌症检测的探针组合的设计方法及其应用
CN113063835B (zh) * 2021-03-19 2022-08-02 中山大学 一种基于元素标记-电感耦合等离子体质谱检测策略的cfDNA分析方法及其应用
CN117858956A (zh) * 2021-08-25 2024-04-09 南京金斯瑞生物科技有限公司 一种用于检测单碱基突变的引物组和基因芯片方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537633T3 (es) 2004-03-02 2015-06-10 The Johns Hopkins University Mutaciones del gen de PIK3CA en cánceres humanos
US9556491B2 (en) * 2007-02-26 2017-01-31 John Wayne Cancer Institute Utility of B-RAF DNA mutation in diagnosis and treatment of cancer
US8071338B2 (en) 2007-08-08 2011-12-06 Roche Molecular Systems, Inc. Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US20100041048A1 (en) * 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
CN102234685B (zh) 2010-04-23 2014-08-27 益善生物技术股份有限公司 一种pik3ca基因突变检测液相芯片
CN103459612A (zh) 2010-12-03 2013-12-18 布兰代斯大学 用于检测野生型群体中的核酸突变体的方法和试剂盒
CN102533958A (zh) 2010-12-28 2012-07-04 苏州科贝生物技术有限公司 一种检测人pik3ca基因突变的方法和试剂盒
WO2012095378A1 (en) 2011-01-11 2012-07-19 Roche Diagnostics Gmbh High resolution melting analysis as a prescreening tool
WO2012131092A2 (en) * 2011-03-31 2012-10-04 Signature Diagnostics Ag Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages
WO2012151560A2 (en) * 2011-05-04 2012-11-08 Biocept, Inc. Methods for detecting nucleic acid sequence variants
SG2014010276A (en) 2011-08-18 2014-03-28 Nestec Sa Compositions and methods for detecting allelic variants
JP2013081450A (ja) 2011-09-27 2013-05-09 Arkray Inc 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット
US11261494B2 (en) * 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
EP2711432A1 (en) 2012-09-21 2014-03-26 Genomica S.A.U. Method for detection of BRAF and PI3K mutations
CN105378160B (zh) * 2013-08-12 2018-04-17 伯乐生命医学产品有限公司 具有碱基配对的寡聚体的扩增报告子

Also Published As

Publication number Publication date
IL250392B (en) 2020-03-31
CN106715723A (zh) 2017-05-24
PT3198026T (pt) 2020-01-16
HUE047958T2 (hu) 2020-05-28
LT3198026T (lt) 2020-01-27
DK3198026T3 (da) 2020-01-20
IL250392A0 (en) 2017-03-30
ES2764423T3 (es) 2020-06-03
CN106715723B (zh) 2021-03-30
RS59710B1 (sr) 2020-01-31
EP3198026B1 (en) 2019-10-09
JP2017523810A (ja) 2017-08-24
US20170233821A1 (en) 2017-08-17
JP6770957B2 (ja) 2020-10-21
CY1122647T1 (el) 2021-03-12
EP3198026A1 (en) 2017-08-02
WO2016020710A1 (en) 2016-02-11
CA2957396C (en) 2021-03-09
SI3198026T1 (sl) 2020-02-28
PL3198026T3 (pl) 2020-05-18
US11279979B2 (en) 2022-03-22
SMT202000005T1 (it) 2020-03-13
CA2957396A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
HRP20192353T1 (hr) Metoda određivanja mutacijskog statusa pik3ca u uzorku
JP2017523810A5 (enExample)
Miotke et al. High sensitivity detection and quantitation of DNA copy number and single nucleotide variants with single color droplet digital PCR
Andersson et al. Properties of targeted preamplification in DNA and cDNA quantification
US20190085401A1 (en) Method for the quantification of pd-l1 expression
Choi et al. MicroRNA-194-5p could serve as a diagnostic and prognostic biomarker in myelodysplastic syndromes
Sefrioui et al. Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients
JP2014519319A5 (enExample)
US20220073996A1 (en) Model for predicting treatment responsiveness based on intestinal microbial information
Backes et al. Blood born miRNAs signatures that can serve as disease specific biomarkers are not significantly affected by overall fitness and exercise
Poláková et al. High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain
Holdhoff et al. Detection of tumor DNA at the margins of colorectal cancer liver metastasis
JP7085235B2 (ja) 膵がん診断キット
ES3024991T3 (en) Methods and kits for determining the efficiency of plasma separation from whole blood
KR20170042725A (ko) 빈발 돌연변이의 신속도 및 민감도 검출 방법
Chinnappan et al. Highly sensitive multiplex detection of microRNA by competitive DNA strand displacement fluorescence assay
Li et al. Isocitrate dehydrogenase 1 gene mutation is associated with prognosis in clinical low-grade gliomas
Tang et al. A single quantum dot-based biosensor for DNA point mutation assay
JP4968577B2 (ja) サイトケラチン１９（ＣＫ１９）ｍＲＮＡの迅速測定法、並びにそのためのプライマー及びプローブ
CN103748237A (zh) 预后方法
Ebbelaar et al. Comparative performance analysis of idylla and archer in the detection of gene fusions in spitzoid melanocytic tumors
JP2022031958A (ja) 分析方法及びキット
Wiedmeier et al. Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women
JP6639054B2 (ja) ハイブリダイゼーションを解析するための方法および手段
Çağdaş et al. Optimization studies and results of recombinase polymerase amplification technique for gene mutation detection